You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. ICU-CARE: An interactive mobile app to enhance the efficiency of daily informal caregiving in the intensive care unit

    SBC: SILICON CURES LLC            Topic: NINR

    PROJECT SUMMARY Actively involving informal caregivers in direct patient care at the bedside in the intensive care unit (ICU) has the potential to improve patient, informal caregiver, and health care system outcomes. Practice guidelines call for the liberal inclusion of informal caregivers as active partners in ICU care, but there is a critical, unmet need to develop tools that effectively operati ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. BEASTS-Novel Biomimetic Liver Platform for Enabling ALD Researchers

    SBC: KESHAVA BIOSCIENCES LLC            Topic: 350

    PROJECT SUMMARY Alcoholic liver disease (ALD) is one of the major causes of morbidity and mortality in the world. Significant challenges remain for developing preventive or curative approaches targeting ALD. No effective treatments for ALD currently exist but for reducing alcohol consumption or liver transplantation. The current paucity of clinically relevant experimental models impedes any effort ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studies

    SBC: EXAVIR THERAPEUTICS INC.            Topic: NIAID

    PROJECT SUMMARY While there are now successful treatment regimens and prevention strategies for people living with HIV/AIDS, the HIV pandemic remains a public health crisis in the United States and worldwide, with nearly 40,000 new infections each year in the US alone. To prevent the spread of HIV in vulnerable populations, the US Preventive Services Task Force has recommended HIV pre-exposure pro ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. CDK2 inhibitors for protecting hearing loss

    SBC: TING THERAPEUTICS LLC            Topic: NIDCD

    CDK2 inhibitors for protecting hearing loss Ting Therapeutics LLC is a pharmaceutical company developing drugs to prevent and treat hearing loss. Cisplatin is one of the most widely used drugs to treat cancers. However cisplatin anticancer therapy causes high frequency hearing loss in 40-60% of the patients. To date, no drugs have been approved by the Food and Drug Administration for protection fr ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Scaling health and bioscience training technology to informal education

    SBC: Discovery Collective, Inc.            Topic: 500

    PROJECT SUMMARY/ABSTRACT Student engagement in hands-on model building, experimental design, and simulation-based exploration has been shown to propel student learning of biological concepts towards increasing complexity. The long-term goal in developing Model It! is to integrate computational models and simulations throughout all K-12 formal and informal science education. The foundation of this ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Preclinical evaluation of an otoprotectant TT002

    SBC: TING THERAPEUTICS LLC            Topic: NIDCD

    Project Summary Ting Therapeutics LLC is a pharmaceutical company developing drugs to prevent and treat hearing loss. Cisplatin is one of the most widely used drugs to treat cancers. However, cisplatin therapy causes hearing loss in 40-60% of the patients. To date, no drugs have been approved by the Food and Drug Administration for protection from cisplatin-induced hearing loss (CIHL). Most candid ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Effect of Multifunctional Redox Modulator (MFRM) HK-2 on Acoustic Blast Overpressure and Cognitive Function

    SBC: Therapeutic Vision, Inc.            Topic: NIDCD

    Acoustic blasts exposure can induce hearing loss and traumatic brain injury (TBI), changes linked to memory dysfunction, cognitive decline, suppression neurogenesis and formation neurotoxic Aβ:Zn plaques in the hippocampus. The blast-induced changes in the inner ear and hippocampus are believed to result from oxidative stress, metal dyshomeostasis, and the increased expression of neurotoxic amylo ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. A novel antioxidant delivery system, Pro-NP™, for protection against UV-related skin cancer

    SBC: PROTRANSIT NANOTHERAPY LLC            Topic: NIAMS

    ABSTRACT This project aims to develop a skincare product to prevent ultraviolet (UV)-induced skin cancer with a novel antioxidant delivery system, Pro-NP™, for topical application alone or as an additive to commercial sunblock. Skin cancer is more common than all other cancers combined and affects millions of Americans every year. UV exposure from the sun or tanning beds causes the production of ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a Targeted Radiotherapeuitc for Pancreatic Ductal Adenocarcinoma

    SBC: ADDUCTNE LLC            Topic: 102

    In 2020 alone, pancreatic cancer is estimated to have resulted in 47,050 deaths in the U.S. making it the fourth leading cause of cancer-related death. Pancreatic ductal adenocarcinoma (PDAC) makes up greater than 90% of all pancreatic cancer diagnoses and has an overall five-year survival rate of just 10%. New therapeutic options are needed to improve the poor prognosis for patients with PDAC. Ex ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  10. ProGel Technology for Better Management of Osteoarthritis Pain

    SBC: ENSIGN PHARMACEUTICAL, INC.            Topic: NIDA

    ABSTRACTAs one of the largest opioid consuming countries in the world, the prevalence of opioid use disorder (OUD) during 2017 is over 5 million in the U.S. alone. The significant increase of opioids use disorder (OUD) cases during the last 2 decades may be partially attributed to our overreliance on the prescription of the opioids for the management of non-cancer chronic pain, such as osteoarthri ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government